ZIM Laboratories Limited (ZIMLAB.NS)
INR 112.56
(0.39%)
INR 112.56
(0.39%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 462.09 Million INR | -29.22% |
| 2022 | 582 Million INR | 31.82% |
| 2021 | 452.62 Million INR | 7.06% |
| 2020 | 368.92 Million INR | 60.15% |
| 2019 | 258.11 Million INR | -40.06% |
| 2018 | 438.99 Million INR | 8.66% |
| 2017 | 439.99 Million INR | 4.59% |
| 2016 | 359.4 Million INR | 19.63% |
| 2015 | 250.78 Million INR | 39.76% |
| 2014 | -114.53 Million INR | -1.73% |
| 2013 | 230.89 Million INR | -15.97% |
| 2012 | 274.78 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 80.36 Million INR | -47.41% |
| 2023 Q1 | 59.45 Million INR | -63.17% |
| 2023 FY | - INR | -29.22% |
| 2023 Q4 | 156.47 Million INR | 23.74% |
| 2023 Q3 | 126.45 Million INR | 17.68% |
| 2023 Q2 | 107.45 Million INR | 80.75% |
| 2022 Q1 | 130.77 Million INR | -14.55% |
| 2022 FY | - INR | 31.82% |
| 2022 Q4 | 161.43 Million INR | 4.18% |
| 2022 Q3 | 154.96 Million INR | 13.26% |
| 2022 Q2 | 136.82 Million INR | 4.63% |
| 2021 FY | - INR | 7.06% |
| 2021 Q2 | 111.39 Million INR | 71.52% |
| 2021 Q4 | 153.04 Million INR | 34.69% |
| 2021 Q3 | 113.63 Million INR | 2.01% |
| 2021 Q1 | 64.94 Million INR | -28.34% |
| 2020 FY | - INR | 60.15% |
| 2020 Q3 | 82.46 Million INR | -35.98% |
| 2020 Q2 | 128.81 Million INR | 15.13% |
| 2020 Q1 | 111.88 Million INR | 39.52% |
| 2020 Q4 | 90.63 Million INR | 9.91% |
| 2019 Q1 | 41.61 Million INR | -58.7% |
| 2019 FY | - INR | -40.06% |
| 2019 Q4 | 80.19 Million INR | -6.97% |
| 2019 Q3 | 86.2 Million INR | 72.03% |
| 2019 Q2 | 50.1 Million INR | 20.42% |
| 2018 Q4 | 100.74 Million INR | -24.46% |
| 2018 FY | - INR | 8.66% |
| 2018 Q3 | 133.37 Million INR | 26.74% |
| 2018 Q2 | 105.23 Million INR | 3.14% |
| 2018 Q1 | 102.02 Million INR | -16.04% |
| 2017 Q3 | 111.89 Million INR | 19.35% |
| 2017 Q1 | 69.59 Million INR | 0.0% |
| 2017 Q2 | 93.75 Million INR | 34.72% |
| 2017 Q4 | 121.51 Million INR | 8.6% |
| 2017 FY | - INR | 4.59% |
| 2016 FY | - INR | 19.63% |
| 2015 FY | - INR | 39.76% |
| 2014 FY | - INR | -1.73% |
| 2013 FY | - INR | -15.97% |
| 2012 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Sigachi Industries Limited | 883.39 Million INR | 47.691% |
| Ind-Swift Limited | 1.06 Billion INR | 56.613% |
| Bajaj HealthCare Limited | 406.23 Million INR | -13.75% |
| Sakar Healthcare Limited | 393.26 Million INR | -17.502% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 99.252% |
| Innova Captab Limited | 1.66 Billion INR | 72.301% |
| Divi's Laboratories Limited | 25.43 Billion INR | 98.183% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 80.393% |
| Morepen Laboratories Limited | 1.72 Billion INR | 73.227% |
| Mankind Pharma Limited | 28.09 Billion INR | 98.355% |
| Sequent Scientific Limited | 549.8 Million INR | 15.952% |
| Wanbury Limited | 985.49 Million INR | 53.11% |
| Laurus Labs Limited | 8 Billion INR | 94.228% |
| Nectar Lifesciences Limited | 1.53 Billion INR | 69.908% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 93.267% |
| Alembic Limited | 1.11 Billion INR | 58.606% |
| Hikal Limited | 2.69 Billion INR | 82.836% |
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 95.195% |
| Neuland Laboratories Limited | 4.74 Billion INR | 90.268% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 95.05% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 95.926% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 82.272% |
| Themis Medicare Limited | 562.6 Million INR | 17.865% |
| RPG Life Sciences Limited | 1.28 Billion INR | 63.941% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 99.178% |
| Lupin Limited | 36.96 Billion INR | 98.75% |
| Amrutanjan Health Care Limited | 681.59 Million INR | 32.204% |
| Wockhardt Limited | 1.08 Billion INR | 57.213% |
| Vaishali Pharma Limited | 31.71 Million INR | -1357.214% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 88.18% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -42.861% |
| Jubilant Pharmova Limited | 8 Billion INR | 94.228% |
| FDC Limited | 3.38 Billion INR | 86.35% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 99.477% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -60.771% |
| Eris Lifesciences Limited | 6.98 Billion INR | 93.386% |
| Venus Remedies Limited | 711.8 Million INR | 35.081% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | 68.757% |
| Par Drugs and Chemicals Limited | 228.17 Million INR | -102.52% |
| Caplin Point Laboratories Limited | 6.18 Billion INR | 92.527% |
| Shilpa Medicare Limited | 2.58 Billion INR | 82.145% |
| Albert David Limited | 1.04 Billion INR | 55.798% |
| Ajanta Pharma Limited | 12.56 Billion INR | 96.322% |
| Hester Biosciences Limited | 539.47 Million INR | 14.342% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 90.12% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 116.375% |
| Gufic Biosciences Limited | 1.48 Billion INR | 68.787% |
| Windlas Biotech Limited | 781.72 Million INR | 40.887% |
| Procter & Gamble Health Limited | 3.07 Billion INR | 84.97% |
| Aarey Drugs & Pharmaceuticals Limited | 45.16 Million INR | -923.131% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -164.137% |
| Granules India Limited | 8.6 Billion INR | 94.629% |
| Aarti Drugs Limited | 3.24 Billion INR | 85.776% |
| Bal Pharma Limited | 345.59 Million INR | -33.712% |
| Alkem Laboratories Limited | 24.19 Billion INR | 98.09% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 99.666% |
| Lincoln Pharmaceuticals Limited | 1.34 Billion INR | 65.6% |
| Medicamen Biotech Limited | 245.66 Million INR | -88.104% |
| Unichem Laboratories Limited | 742.35 Million INR | 37.753% |
| Bafna Pharmaceuticals Limited | 114.58 Million INR | -303.286% |
| Biofil Chemicals and Pharmaceuticals Limited | 12.99 Million INR | -3455.686% |
| Valiant Laboratories Limited | 12.73 Million INR | -3527.42% |
| Orchid Pharma Limited | 1.41 Billion INR | 67.439% |
| Medico Remedies Limited | 129.09 Million INR | -257.954% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 93.265% |
| Ipca Laboratories Limited | 13.29 Billion INR | 96.525% |
| Brooks Laboratories Limited | 41.72 Million INR | -1007.403% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -7.395% |
| Piramal Enterprises Limited | -3.86 Billion INR | 111.968% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 98.68% |
| NATCO Pharma Limited | 18.79 Billion INR | 97.541% |
| Suven Life Sciences Limited | -992.78 Million INR | 146.546% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 658.581% |
| Strides Pharma Science Limited | 3.76 Billion INR | 87.725% |
| Indoco Remedies Limited | 2.64 Billion INR | 82.543% |
| Alpa Laboratories Limited | 229.96 Million INR | -100.946% |
| Lasa Supergenerics Limited | -65.08 Million INR | 810.045% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 112.384% |